Grifols Q3 2026 slides: margin expansion drives leverage below 4x

Grifols reported Q3 2026 revenue of €2,040 million, up 8.4% at constant currency, and adjusted EBITDA of €538 million, up 9.8%, with margin expanding 60bps to 26.4%. Net leverage fell to 3.98x, while nine-month free cash flow before M&A rose €110 million year over year to €298 million; management also announced an interim dividend of €0.15 per share and reiterated its 2026 guidance, including a 25% adjusted EBITDA margin target. Albumin revenue declined 13.2% amid continued China weakness, and Q4 biopharma growth is expected to be more modest; shares rose 5% to $8.52 after the presentation.

Analysis

The key change is not the sub-4x headline but a lower probability of a balance-sheet-driven equity impairment: stronger cash conversion and no near-term maturity wall give Grifols more time to execute. That can support multiple normalization, but leverage remains high enough that a reversal in cash generation would quickly restore financing risk. The next test is whether growth converts to cash after working-capital needs and investment in plasma capacity—not simply whether reported EBITDA rises.

Near term, the 5% reaction risks pulling forward some of the de-risking trade. Management’s expectation for more modest Q4 biopharma growth makes a clean earnings beat less likely, while EUR/USD translation can obscure underlying progress. Over 1–3 months, SPARTA results are a binary catalyst: a favorable read could improve the Alpha-1 opportunity, but clinical efficacy and eventual commercial uptake remain separate hurdles. Over 6–18 months, Egypt could improve sourcing economics and supply resilience, conditional on collection scale, regulatory execution, and usable yields; it should not yet be capitalized as delivered margin improvement.

The main counterweight is China albumin. A slower normalization would prolong a segment drag even if immunoglobulin demand remains healthy. The market may also be underweight the value of reduced refinancing risk, but management’s claims of durable margin and cash-flow improvement need another reporting cycle of verification.

Key Decisions for Investors

• Avoid chasing the post-results gap. For an equity position, use a starter on consolidation or a pullback, and add only if the next report confirms cash conversion and continued organic deleveraging; no price target is justified from the supplied data.
• Treat GRFS as a conditional balance-sheet recovery exposure, not yet a fully de-risked compounder. Monitor free cash flow before M&A, net leverage, cash interest, and working-capital investment; deterioration in cash conversion or a leverage rebound would falsify the recovery thesis.
• Keep China albumin normalization as a watch item rather than underwriting a 2027 rebound. Look for evidence of channel inventory clearing and stabilization in albumin revenue; continued weakness would offset IG and Egypt progress.
• Do not assign material value to Egypt or SPARTA ahead of validation. Track collection volumes and contribution to sourcing economics, and assess SPARTA efficacy separately from regulatory and commercial prospects; execution delays or an unfavorable trial result are downside catalysts.